序号 | 专利名 | 申请号 | 申请日 | 公开(公告)号 | 公开(公告)日 | 发明人 |
---|---|---|---|---|---|---|
61 | CONJUGATED LINOLEIC ACID ISOMERASE AND A PROCESS FOR THE PRODUCTION OF CONJUGATED LINOLEIC ACID | EP02747365.1 | 2002-06-10 | EP1399569B1 | 2008-09-10 | STANTON, Catherine, Teagasc Dairy Products Research Centre; ROSS, R. Paul, Teagasc Dairy Products Research Centre; ZELDER, Oskar; KAESLER, Bruno |
The present invention relates to a process for the production of conjugated linoleic acid and a process for the production of triglycerides with an increased content of conjugated linoleic acid. Moreover, the invention relates to a nucleic acid sequence; a nucleic acid construct, a vector and transgenic organisms comprising at least one nucleic acid sequence or one nucleic acid construct which encodes a polypeptide with conjugated linoleic isomerase activity. Furthermore, the invention relates to the use of a microorganism of the genus Bifidobacterium as a probiotic. | ||||||
62 | METHOD FOR TREATING AND/OR PREVENTING INFECTIONS IN INFANTS DELIVERED VIA CAESAREAN SECTION | EP06799536.5 | 2006-10-06 | EP1940245A1 | 2008-07-09 | SCHMITT, Joachim; STAHL, Bernd; KNOL, Jan |
The present invention relates to methods for feeding and to compositions to be adminis | ||||||
63 | PET FOOD COMPOSITION FOR SKIN PHOTOPROTECTION | EP03742552.7 | 2003-02-18 | EP1478242A1 | 2004-11-24 | BRETON, Lionel; BUREAU-FRANZ, Isabelle |
An ingestable composition for the photoprotection of the skin of pets which comprises a photoprotecting effective amount of i) at least one probiotic lactic acid bacterium or a culture supernatant thereof, and ii) at least one yeast and/or a carotenoid or derivative, included into an ingestable carrier. | ||||||
64 | FERMENTED FOODS CONTAINING BIFIDOBACTERIUM | EP00963042.7 | 2000-10-02 | EP1224867A1 | 2002-07-24 | MATSUKI, Takahiro; SONOIKE, Koichiro; YASUDA, Emi; IINO, Tohru; ISHIKAWA, Fumiyasu; TOCHIYA, Kaoru |
Fermented foods having a sufficient stability and an excellent flavor as foods to be taken orally are produced by using a bifidobacterium belonging to Bifidobacterium catenulatum or Bifidobacterium pseudocatenulatum which has never been employed in foods so far. These fermented foods containing a bifidobacterium are obtained by fermenting a medium containing soybean milk as the main component by using a bifidobacterium selected from Bifidobacterium catenulatum and Bifidobacterium pseudocatenulatum. |
||||||
65 | COMPOSITION FOR USE IN STIMULATING THE INTESTINAL FLORA IN INFANTS DELIVERED BY CAESAREAN SECTION | EP17205437.1 | 2006-10-20 | EP3326634A2 | 2018-05-30 | Boehm, Günther; Knol, Jan; Stahl, Bernd |
The present invention relates to compositions to be administered to infants delivered via caesarian section and in particular to the use of a) at least two different microorganisms; or b) at least one microorganism and at least one indigestible oligosaccharide; or c) at least two, preferably three, different Bifidobacteria species, subspecies or strains for the manufacture of a composition for enteral administration to an infant delivered via caesarean section. Thereby it is possible to stimulate the healthy development of the intestinal flora of said infants. |
||||||
66 | Composition for stimulating the intestinal flora of infants delivered by caesarean section | EP13171226.7 | 2006-10-20 | EP2638812B1 | 2018-03-21 | Boehm, Günther; Knol, Jan; Stahl, Bernd |
The present invention relates to methods for feeding and to compositions to be adminis | ||||||
67 | BIFIDOBACTERIUM CECT 7765 AND USE THEREOF IN THE PREVENTION AND/OR TREATMENT OF EXCESS WEIGHT, OBESITY AND RELATED PATHOLOGIES | EP11846843.8 | 2011-12-07 | EP2650002A1 | 2013-10-16 | SANZ HERRANZ, Yolanda; ARLETTE SANTACRUZ, Yolanda; GAUFFIN, Paola |
The present invention relates to the Bifidobacterium CECT 7765 strain, to its cell components, metabolites, and secreted molecules, to the combinations thereof with other microorganisms, and to compositions comprising the aforementioned products, as well as to the use of a strain of the Bifidobacterium pseudocatenulatum species, or to using the CECT 7765 strain for the prevention and/or treatment of obesity, overweight, hyperglycemia and diabetes, preferably type 2 diabetes mellitus, hepatic steatosis or fatty liver, dyslipidemia, metabolic syndrome, immune system dysfunction associated with obesity and overweight; and an unbalanced composition of the intestinal microbiota associated with obesity and overweight. |
||||||
68 | PREVENTING DISEASES IN INFANTS DELIVERED VIA CAESAREAN SECTION | EP06799537.3 | 2006-10-06 | EP1940246B1 | 2010-08-11 | SCHMITT, Joachim; STAHL, Bernd; KNOL, Jan |
The present invention relates to methods for feeding and to compositions to be adminis | ||||||
69 | METHOD FOR TREATING AND/OR PREVENTING INFECTIONS IN INFANTS DELIVERED VIA CAESAREAN SECTION | EP06799536.5 | 2006-10-06 | EP1940245B1 | 2009-08-26 | SCHMITT, Joachim; STAHL, Bernd; KNOL, Jan |
The present invention relates to methods for feeding and to compositions to be adminis | ||||||
70 | METHOD FOR STIMULATING THE INTESTINAL FLORA | EP06806443.5 | 2006-10-20 | EP1940250A1 | 2008-07-09 | BOEHM, Günther; STAHL, Bernd; KNOL, Jan |
The present invention relates to methods for feeding and to compositions to be adminis | ||||||
71 | METHOD FOR STIMULATING INTESTINAL BARRIER INTEGRITY AFTER NON-NATURAL BIRTH | EP06799538.1 | 2006-10-06 | EP1940247A2 | 2008-07-09 | SCHMITT, Joachim; BOEHM, Gunther; BEERMANN, Christopher |
The present invention relates to methods for feeding and to compositions to be adminis | ||||||
72 | Method for stimulating the intestinal flora | EP05023029.1 | 2005-10-21 | EP1776877A1 | 2007-04-25 | Boehm, Guenther, Prof. Dr.; Knol, Jan; Stahl, Bernd, Dr. |
The present invention relates to methods for feeding and to compositions to be administered to infants delivered via caesarian section and in particular to the use of a) at least two different microorganisms; or b) at least one microorganism and at least one indigestible oligosaccharide; or c)at least two different Bifidobacteria species, subspecies or strains for the manufacture of a composition for enteral administration to an infant delivered via caesarean section. Thereby it is possible to stimulate the healthy development of the intestinal flora of said infants. |
||||||
73 | PROCESS FOR PRODUCING CONJUGATED FATTY ACID AND FOOD/DRINK OBTAINED BY THE PROCESS | EP03746461 | 2003-04-11 | EP1500706A4 | 2005-08-03 | MIZUSAWA NAOMI; SAKAI MASASHI; KUDO SATOSHI; SHIRASAWA YUKIO |
A conjugated fatty acid typified by cis-9, trans-11 conjugated linoleic acid seemingly having a high physiological activity is selectively and highly efficiently produced by conjugating an unsaturated fatty acid having at least two double bonds with the use of viable cells, dead cells or a cell extract of one or more bacteria having a conjugation ability selected from the group consisting of Lactobacillus oris, Lactobacillus pontis, Lactobacillus panis, Bifidobacterium breve, Bifidobacterium bifidium, Bifidobacterium infantis and Bifidobacterium pseudocatenulatum or an enzyme obtained therefrom. | ||||||
74 | PROCESS FOR PRODUCING CONJUGATED FATTY ACID AND FOOD/DRINK OBTAINED BY THE PROCESS | EP03746461.7 | 2003-04-11 | EP1500706A1 | 2005-01-26 | MIZUSAWA, Naomi Kabushiki Kaisha Yakult Honsha; SAKAI, Masashi Kabushiki Kaisha Yakult Honsha; KUDO, Satoshi Kabushiki Kaisha Yakult Honsha; SHIRASAWA, Yukio Kabushiki Kaisha Yakult Honsha |
A conjugated fatty acid such as the cis-9, trans-11 isomer of conjugated linoleic acid having high bioactivities is selectively and efficiently produced by conjugating an unsaturated fatty acid having at least two double bonds with the use of viral cells, dead cells or a cell extract of at least one bacterium selected from the group consisting of Lactobacillus oris, Lactobacillus pontis, Lactobacillus panis, Bifidobacterium breve, Bifidobacterium bifidum, Bifidobacterium infantis and Bifidobacterium pseudocatenulatum, or an enzyme derived from the bacterium. |
||||||
75 | CONJUGATED LINOLEIC ACID ISOMERASE AND A PROCESS FOR THE PRODUCTION OF CONJUGATED LINOLEIC ACID | EP02747365.1 | 2002-06-10 | EP1399569A2 | 2004-03-24 | STANTON, Catherine,Teagasc Dairy Prod Resch Cent.; ROSS, R. Paul,Teagasc Dairy Products Resch Centre; ZELDER, Oskar |
The present invention relates to a process for the production of conjugated linoleic acid and a process for the production of triglycerides with an increased content of conjugated linoleic acid. Moreover, the invention relates to a nucleic acid sequence; a nucleic acid construct, a vector and transgenic organisms comprising at least one nucleic acid sequence or one nucleic acid construct which encodes a polypeptide with conjugated linoleic isomerase activity. Furthermore, the invention relates to the use of a microorganism of the genus Bifidobacterium as a probiotic. | ||||||
76 | CLA biosynthesis by bifidobacteria | EP01113962.3 | 2001-06-08 | EP1264893A1 | 2002-12-11 | The designation of the inventor has not yet been filed |
Nineteen strains of Lactobacillus, 2 strains of Lactococcus, 1 strain of Pediococcus, 4 strains of Propionibacterium and 23 strains of Bifidobacterium were screened for their ability to produce conjugated linoleic acid (CLA) from linoleic acid. Of these, 7 strains of Bifidobacterium, as well as 2 strains of Propionibacterium produced the cis-9, trans-11 CLA isomer from linoleic acid. In contrast, strains of Lactobacillus, Lactococcus and Pediococcus lacked the ability to synthesise CLA. CLA (cis-9, trans-11 isomer) production by the genus Bifidobacterium was shown to exhibit considerable interspecies variation, with B. breve and B. dentium being the most efficient producers among the strains tested, yielding up to 65 % conversion of linoleic acid to CLA at linoleic acid concentrations of 0.2-1.0 mg/ml in MRS medium. The growth of B. breve strains was inhibited by increasing concentrations of linoleic acid. Viability of B. breve 2257 was unaffected in the presence of up to 0.5 mg/ml linoleic acid for 48 h but was dramatically reduced to 1.5% survival at 1 mg/ml linoleic acid. However, viability of the B. breve strains NCFB2258, NCTC 11815, NCIMB 8815 and NCIMB 8807 was reduced to < 60 % at linoleic acid concentrations of 0.2 mg/ml. These data suggest that certain strains of bifidobacteria may have applications to elevate CLA content of food products and CLA status in humans. |
||||||
77 | METHOD FOR STIMULATING INTESTINAL BARRIER INTEGRITY AFTER NON-NATURAL BIRTH | PCT/NL2006050248 | 2006-10-06 | WO2007046699A3 | 2007-11-01 | SCHMITT JOACHIM; BOEHM GUNTHER; BEERMANN CHRISTOPHER |
The present invention relates to methods for feeding and stimulating the health of infants delivered via caesarean section comprising administering long chain polyunsaturated fatty acids and/or nucleotides. | ||||||
78 | 공역화 리놀렌산을 생산하는 신규한 균주, 이를 함유하는 캡슐제 및 이를 이용한 기능성 식품 | KR1020030023164 | 2003-04-12 | KR100516377B1 | 2005-09-26 | 김소미; 오덕근; 백대헌; 신홍식; 박시호; 이유진; 엄수종; 노영쇠; 박종섭 |
본 발명은 공역화 리놀레인산(CLA)을 생산할 수 있는 신규한 균주에 관한 것이다. 본 발명의 균주에는 비피도박테리움 브레베( Bifidobacterium breve ) CBG-C2 균주, 비피도박테리움 슈도카르테눌라툼( Bifidobacterium pseudocartenulatum ) CBG-C4 균주 및 엔테로코커스 패시움( Enterococcus faecium ) CBG-C5 균주가 포함된다. 본 발명의 균주는 CLA 생산 능력이 우수하며, CLA를 생성하여 배지로 분비하는 한편 균체 내에 축적할 수 있다. 또한 본 발명의 균주는 위산이나 담즙 등의 산과 항생물질에 대해 강한 내성을 지닌다. 본 발명의 균주를 포함하는 조성물은 수용성 다당류로 이루어진 피복물질 내에 본 발명의 균주와 CLA를 포함하는 캡슐제 형태로 제조되어, 기능성 식품 및 의약품으로 사용될 수 있다. | ||||||
79 | 공역화 리놀렌산을 생산하는 신규한 균주, 이를 함유하는 캡슐제 및 이를 이용한 기능성 식품 | KR1020050004128 | 2005-01-17 | KR100514593B1 | 2005-09-13 | 김소미; 오덕근; 백대헌; 신홍식; 박시호; 이유진; 엄수종; 노영쇠; 박종섭 |
본 발명은 공역화 리놀레인산(CLA)을 생산할 수 있는 신규한 균주에 관한 것이다. 본 발명의 균주에는 비피도박테리움 브레베( Bifidobacterium breve ) CBG-C2 균주, 비피도박테리움 슈도카르테눌라툼( Bifidobacterium pseudocartenulatum ) CBG-C4 균주 및 엔테로코커스 패시움( Enterococcus faecium ) CBG-C5 균주가 포함된다. 본 발명의 균주는 CLA 생산 능력이 우수하며, CLA를 생성하여 배지로 분비하는 한편 균체 내에 축적할 수 있다. 또한 본 발명의 균주는 위산이나 담즙 등의 산과 항생물질에 대해 강한 내성을 지닌다. 본 발명의 균주를 포함하는 조성물은 수용성 다당류로 이루어진 피복물질 내에 본 발명의 균주와 CLA를 포함하는 캡슐제 형태로 제조되어, 기능성 식품 및 의약품으로 사용될 수 있다. | ||||||
80 | 공역화 리놀렌산을 생산하는 신규한 균주, 이를 함유하는 캡슐제 및 이를 이용한 기능성 식품 | KR1020050004127 | 2005-01-17 | KR100514592B1 | 2005-09-13 | 김소미; 오덕근; 백대헌; 신홍식; 박시호; 이유진; 엄수종; 노영쇠; 박종섭 |
본 발명은 공역화 리놀레인산(CLA)을 생산할 수 있는 신규한 균주에 관한 것이다. 본 발명의 균주에는 비피도박테리움 브레베( Bifidobacterium breve ) CBG-C2 균주, 비피도박테리움 슈도카르테눌라툼( Bifidobacterium pseudocartenulatum ) CBG-C4 균주 및 엔테로코커스 패시움( Enterococcus faecium ) CBG-C5 균주가 포함된다. 본 발명의 균주는 CLA 생산 능력이 우수하며, CLA를 생성하여 배지로 분비하는 한편 균체 내에 축적할 수 있다. 또한 본 발명의 균주는 위산이나 담즙 등의 산과 항생물질에 대해 강한 내성을 지닌다. 본 발명의 균주를 포함하는 조성물은 수용성 다당류로 이루어진 피복물질 내에 본 발명의 균주와 CLA를 포함하는 캡슐제 형태로 제조되어, 기능성 식품 및 의약품으로 사용될 수 있다. |